ACADIA Pharmaceuticals Competitors

ACADIA Pharmaceuticals (NASDAQ:ACAD) and BeiGene (NASDAQ:BGNE) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, BeiGene has a beta of 0.91, meaning that its share price is 9% less volatile than the S&P 500.

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and BeiGene's revenue, earnings per share (EPS) and valuation.

ACADIA Pharmaceuticals has higher earnings, but lower revenue than BeiGene. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than BeiGene, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.7% of BeiGene shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 9.0% of BeiGene shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and BeiGene, as reported by MarketBeat.

ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. BeiGene has a consensus price target of $310.00, indicating a potential upside of 1.79%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than BeiGene.

Profitability

This table compares ACADIA Pharmaceuticals and BeiGene's net margins, return on equity and return on assets.

Summary

ACADIA Pharmaceuticals beats BeiGene on 12 of the 15 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Genmab A/S (NASDAQ:GMAB) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Genmab A/S has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500.

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and Genmab A/S's revenue, earnings per share (EPS) and valuation.

Genmab A/S has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.2% of Genmab A/S shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Genmab A/S, as reported by MarketBeat.

ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. Genmab A/S has a consensus price target of $42.1429, indicating a potential upside of 29.47%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Genmab A/S.

Profitability

This table compares ACADIA Pharmaceuticals and Genmab A/S's net margins, return on equity and return on assets.

Summary

Genmab A/S beats ACADIA Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

ACADIA Pharmaceuticals (NASDAQ:ACAD) and Horizon Therapeutics Public (NASDAQ:HZNP) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, valuation and institutional ownership.

Risk and Volatility

ACADIA Pharmaceuticals has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Horizon Therapeutics Public has a beta of 1.15, meaning that its share price is 15% more volatile than the S&P 500.

Insider & Institutional Ownership

93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. Comparatively, 88.6% of Horizon Therapeutics Public shares are owned by institutional investors. 27.7% of ACADIA Pharmaceuticals shares are owned by insiders. Comparatively, 4.3% of Horizon Therapeutics Public shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for ACADIA Pharmaceuticals and Horizon Therapeutics Public, as reported by MarketBeat.

ACADIA Pharmaceuticals presently has a consensus price target of $62.2667, indicating a potential upside of 31.25%. Horizon Therapeutics Public has a consensus price target of $101.8889, indicating a potential upside of 11.95%. Given ACADIA Pharmaceuticals' higher probable upside, research analysts plainly believe ACADIA Pharmaceuticals is more favorable than Horizon Therapeutics Public.

Profitability

This table compares ACADIA Pharmaceuticals and Horizon Therapeutics Public's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares ACADIA Pharmaceuticals and Horizon Therapeutics Public's revenue, earnings per share (EPS) and valuation.

Horizon Therapeutics Public has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Horizon Therapeutics Public, indicating that it is currently the more affordable of the two stocks.

Catalent (NYSE:CTLT) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Catalent has a beta of 1.5, indicating that its stock price is 50% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Insider & Institutional Ownership

97.8% of Catalent shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 1.0% of Catalent shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Catalent and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Catalent currently has a consensus target price of $125.1250, indicating a potential upside of 15.46%. ACADIA Pharmaceuticals has a consensus target price of $62.2667, indicating a potential upside of 31.25%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Catalent.

Profitability

This table compares Catalent and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Catalent and ACADIA Pharmaceuticals' revenue, earnings per share and valuation.

Catalent has higher revenue and earnings than ACADIA Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalent, indicating that it is currently the more affordable of the two stocks.

Summary

Catalent beats ACADIA Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Royalty Pharma (NASDAQ:RPRX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both finance companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Insider & Institutional Ownership

40.9% of Royalty Pharma shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.5% of Royalty Pharma shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Royalty Pharma and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Royalty Pharma currently has a consensus target price of $51.8750, indicating a potential upside of 19.06%. ACADIA Pharmaceuticals has a consensus target price of $62.2667, indicating a potential upside of 31.25%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Royalty Pharma.

Profitability

This table compares Royalty Pharma and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Royalty Pharma and ACADIA Pharmaceuticals' revenue, earnings per share and valuation.

Royalty Pharma has higher earnings, but lower revenue than ACADIA Pharmaceuticals.

Summary

ACADIA Pharmaceuticals beats Royalty Pharma on 7 of the 10 factors compared between the two stocks.

Alnylam Pharmaceuticals (NASDAQ:ALNY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Volatility & Risk

Alnylam Pharmaceuticals has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.

Insider & Institutional Ownership

92.4% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.5% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 27.7% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings for Alnylam Pharmaceuticals and ACADIA Pharmaceuticals, as provided by MarketBeat.com.

Alnylam Pharmaceuticals currently has a consensus target price of $163.4211, indicating a potential upside of 13.24%. ACADIA Pharmaceuticals has a consensus target price of $62.2667, indicating a potential upside of 31.25%. Given ACADIA Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe ACADIA Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Profitability

This table compares Alnylam Pharmaceuticals and ACADIA Pharmaceuticals' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Alnylam Pharmaceuticals and ACADIA Pharmaceuticals' revenue, earnings per share and valuation.

ACADIA Pharmaceuticals has higher revenue and earnings than Alnylam Pharmaceuticals. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

ACADIA Pharmaceuticals beats Alnylam Pharmaceuticals on 11 of the 15 factors compared between the two stocks.